Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-(5-benzenesulfonylamino-1-methyl-1H-benzoimidazol-2-ylmethyl)-benzamidine
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule belonging to the class of benzamidines and sulfanilides. It has the molecular formula C22H21N5O2S and a molecular weight of approximately 419.5 g/mol[1][6][8]. The structure features a benzimidazole core substituted with a benzenesulfonylamino group and an amidine moiety. There is no evidence that this compound has been approved for any therapeutic use or entered clinical trials beyond preclinical or experimental stages[2]. Its mechanism of action, pharmacological activity, primary indication, developer(s), and detailed biological effects are not described in publicly available sources as of June 2025.
- Other names
- 4-(5-BENZENESULFONYLAMINO-1-METHYL-1H-BENZOIMIDAZOL-2-YLMETHYL)-BENZAMIDINE4-(5-benzenesulfonamido-1-methyl-1H-benzodiazol-2-yl)methyl)benzene-carboximidamide4-[ (5-benzenesulfonamido -1-methyl -1h -1,3-benzodiazol -2 yl )methyl ]benzene -carboximidamide
02
Targets
F2 (Thrombin)
Beyond the preview
Go deeper on 4-(5-benzenesulfonylamino-1-methyl-1H-benzoimidazol-2-ylmethyl)-benzamidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-(5-benzenesulfonylamino-1-methyl-1H-benzoimidazol-2-ylmethyl)-benzamidine.